TLDR The research identified genes and non-coding RNAs in cells that could be affected by testosterone, which may help understand hair loss and prostate cancer.
The study aimed to identify genes affected by testosterone signaling in dermal papilla cells (DPCs), which could help understand androgenetic alopecia (AGA). The researchers found that the androgen receptor (AR) is suppressed in human DPCs. After introducing AR into DPCs, they found that the expression of caveolin-1 is suppressed in AR-expressing DPCs, but recovers after dihydroxy testosterone (DHT) treatment. The study identified 27 downregulated genes and 130 upregulated genes as potential candidates for downstream genes of AR signaling pathways. The study also identified 168 differentially expressed non-coding RNAs, which could control gene expression. The data sets could be useful for studying the effect of AR signaling on prostate cancers and AGA.
Cited in this study
5 / 5 results
1 citations
,
January 2022 in “BMC Genomic Data” The study found that androgen receptors in skin cells mainly affect the focal adhesion pathway and control the caveolin-1 gene, with implications for new treatments for related diseases.
5 citations
,
January 2021 in “iScience” Using a combination of specific cell cycle regulators is better for safely keeping hair root cells alive indefinitely compared to cancer-related methods.
8 citations
,
March 2020 in “Frontiers in Cell and Developmental Biology” Researchers created immortal human skin cells with constant testosterone receptor activity to study hair loss and test treatments.
11 citations
,
March 2019 in “Assay and Drug Development Technologies” Natural herbal compounds might treat certain medical conditions by reducing DHT levels, but more research is needed to confirm their effectiveness and safety.
171 citations
,
February 2008 in “Journal of Investigative Dermatology” A substance called DKK-1 increases in balding areas and causes hair cells to die when exposed to DHT.
24 citations
,
February 2012 in “Prostate cancer and prostatic diseases” 5α-reductase inhibitors help shrink the prostate, improve urinary symptoms, and may reduce prostate cancer risk.
